Werewolf Therapeutics, Inc.
HOWL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785530
In the last 90 days, Werewolf Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 45 institutions reported holding it in 13F filings for Q2 2026, worth $3.91M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Werewolf Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $44.7K in total
- Insiders trading
- 1
- Net value
- −$44.7K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Werewolf Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Evnin Luke | Director | 0Indirect | Jul 8, 2026 | 31 |
| RA Capital Healthcare Fund LP | 10% Owner | 303,719Indirect | Jun 22, 2026 | 4 |
| Ra Capital Management, L.P. | 10% Owner | 303,719Indirect | Jun 22, 2026 | 4 |
| Kolchinsky Peter | 10% Owner | 303,719Indirect | Jun 22, 2026 | 4 |
| Shah Rajeev M. | 10% Owner | 303,719Indirect | Jun 22, 2026 | 4 |
| MPM BioVentures 2014, L.P. | Other: Former 10% Owner | 4,784,111Indirect | Dec 4, 2025 | 9 |
| MPM BioVentures 2014 (B), L.P. | Other: Former 10% Owner | 4,784,111Indirect | Dec 4, 2025 | 9 |
| MPM Asset Management Investors BV2014 LLC | Other: Former 10% Owner | 4,784,111Indirect | Dec 4, 2025 | 9 |
| MPM BioVentures 2014 LLC | Other: Former 10% Owner | 4,784,111Indirect | Dec 4, 2025 | 9 |
| MPM BioVentures 2014 GP LLC | Other: Former 10% Owner | 4,784,111Indirect | Dec 4, 2025 | 9 |
| Gadicke Ansbert | Other: Former 10% Owner | 4,784,111Indirect | Dec 4, 2025 | 9 |
| MPM Asset Management LLC | Other: Former 10% Owner | 4,784,111Indirect | Dec 4, 2025 | 9 |
| MPM BioImpact LLC | Other: Former 10% Owner | 4,784,111Indirect | Dec 4, 2025 | 9 |
| UBS Oncology Impact Fund L.P. | Other: Former 10% Owner | 4,784,111Indirect | Dec 4, 2025 | 9 |
| MPM Oncology Innovations Fund LP | Other: Former 10% Owner | 4,784,111Indirect | Dec 4, 2025 | 9 |
| Oncology Impact Fund (Cayman) Management L.P. | Other: Former 10% Owner | 4,784,111Indirect | Dec 4, 2025 | 9 |
| MPM Oncology Innovations Fund GP LLC | Other: Former 10% Owner | 4,784,111Indirect | Dec 4, 2025 | 9 |
| Sherman Michael A. | Director | – | Jun 13, 2025 | 0 |
| Morrison Briggs | Director | – | Jun 13, 2025 | 0 |
| Lazarus Alon | Director | – | Jun 13, 2025 | 0 |
| Chatterjee Meeta | Director | – | Jun 13, 2025 | 0 |
| Singhal Anil K. | Director | – | Jun 13, 2025 | 0 |
| Atkins Michael B. | Director | – | Jun 13, 2025 | 0 |
| RA Capital Nexus Fund II, L.P. | Director, 10% Owner | 6,237,482Indirect | May 14, 2025 | 0 |
| Bloom Steven H. | Chief Business Officer | – | May 2, 2025 | 0 |
| Foley Todd | 10% Owner | 3,208,793Indirect | Apr 30, 2025 | 0 |
| Hicklin Daniel J | See Remarks | – | Jan 6, 2025 | 0 |
| Trost Timothy W. | Chief Financial Officer | – | Jan 6, 2025 | 0 |
| Isaacs Randi | Chief Medical Officer | – | Jan 6, 2025 | 0 |
| Lubman Ellen | Chief Business Officer | – | Jan 6, 2025 | 0 |
| Karunatilake Chulani | Chief Technology Officer | – | Jan 6, 2025 | 0 |
| DiRocco Derek | Director | – | May 24, 2024 | 0 |
| Seidel-Dugan Cynthia | Chief Scientific Officer | 164,888 | Jan 4, 2024 | 0 |
| Leonard Reid | Chief Operating Officer | 14,102 | Jan 9, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 29, 2025 (view filing)7:21 PM ET | Oct 27-29 | 2 days | MPM BioVentures 2014, L.P. and 4 others10% Owner | SSale | −276.0K | $1.62 | −$446.4K | −4.1%6.44M after | 3 lots10b5-1Duplicate filing |
| Oct 29, 2025 (view filing)7:21 PM ET | Oct 27-29 | 2 days | Gadicke Ansbert and 6 others10% Owner | SSale | −276.0K | $1.62 | −$446.4K | −4.1%6.44M after | 3 lots10b5-1 |
| Oct 29, 2025 (view filing) | Oct 27-29 | 2 days | Evnin LukeDirector | SSale | −177.1K | $1.62 | −$286.5K | −4.1%4.13M after | 3 lots10b5-1 |
| May 14, 2025 (view filing)6:08 PM ET | May 12-14 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchase | +536.4K | $0.9082 | +$487.2K | +9.4%6.24M after | 3 lots |
| Apr 30, 2025 (view filing)4:17 PM ET | Mar 27 | 34 daysLate | Foley Todd and 5 others10% Owner | SSale | −1.96K | $1.05 | −$2.06K | −0.1%3.21M after | |
| Apr 30, 2025 (view filing)4:09 PM ET | Mar 27 | 34 daysLate | Evnin LukeDirector, 10% Owner | SSale | −2.42K | $1.05 | −$2.55K | −0.1%4.31M after | |
| Apr 30, 2025 (view filing)4:08 PM ET | Mar 27 | 34 daysLate | Gadicke Ansbert and 6 others10% Owner | SSale | −4.39K | $1.05 | −$4.61K | −0.1%6.72M after | |
| Jan 10, 2023 (view filing)5:14 PM ET | Jan 6 | 4 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | PPurchase | +1.85M | $2.21 | +$4.10M | +48.2%5.70M after | |
| Dec 17, 2021 (view filing) | Dec 15 | 2 days | Leonard ReidChief Operating Officer | SSale | −3.00K | $13.42 | −$40.2K | −2.4%122.2K after | 2 lots |